2025 Outlook: 340B, Infusion and Third-Party Administration
Remy's January 2025 outlook on 340B oversight, third-party administration and infusion care, and the operational shifts it anticipated for FQHCs.
Remy Healthcare Team
6 min read · January 30, 2025 · Updated August 11, 2026
Editor's note: This article was published in January 2025 and reflects our outlook at that time. We have kept the original analysis intact for the record. For where 340B policy stands now, see The 340B Rebate Model: What Covered Entities Need to Know.
Healthcare leaders do not need a perfect forecast to prepare. They need a working view of where policy, reimbursement, and operational pressure are likely to land. For FQHCs and safety-net providers, that means paying close attention to 340B oversight, the evolution of third-party administration, and outpatient infusion care.
The organizations that adapt fastest are usually the ones that prepare before a policy change lands, not after it.
Key Takeaways
- 340B pressure is likely to keep increasing around documentation, transparency, and operational discipline.
- TPA strategy is becoming more technology-driven, especially in claims, compliance, and workflow automation.
- In our work with providers, outpatient infusion demand keeps growing, but reimbursement and staffing pressure make operating efficiency more important.
- FQHCs that invest early in data visibility and workflow design will be better positioned than organizations that react late.
340B is heading into a more demanding operating environment
The 340B program remains strategically essential for covered entities, but the direction of travel is clear: more scrutiny, more documentation pressure, and less tolerance for operational ambiguity.
Even when policy details move slowly, providers should plan for a world where:
- eligibility documentation is reviewed more carefully
- manufacturer restrictions and disputes continue shaping workflow
- audit readiness matters more than policy interpretation alone
- claims, inventory, and patient qualification data need to be easier to defend
For many teams, the biggest change is not the rule itself. It is the amount of operational rigor required to stay comfortable inside the rule.
Compliance maturity will separate strong programs from stressed programs
Some organizations experience a year like this as disruption. Others experience it as validation because they already built cleaner systems.
That difference usually comes down to whether the program has:
- dependable patient qualification logic
- auditable documentation trails
- timely reporting and reconciliation
- clear ownership of compliance operations
If your 340B program still depends on manual workarounds, inconsistent documentation, or vendor black boxes, the next policy cycle is more likely to feel expensive than strategic.
TPA strategy is becoming a technology decision
Third-party administration used to be framed mostly as an outsourcing choice. Increasingly, it is a systems decision.
The best TPA environments are using automation and analytics to improve:
- claims throughput
- denial prevention
- eligibility verification
- compliance flagging
- reporting speed
That matters because healthcare operators are under pressure to do more with leaner teams. A TPA model that cannot improve visibility and consistency will start to feel dated quickly.
This is the operating model behind Remy's 340B TPA services: eligibility and onboarding, compliance assurance, vendor integration, provider coordination, inventory management, and revenue cycle handled as one accountable system rather than a set of disconnected handoffs.
Where AI and automation are likely to matter most
Not every workflow needs artificial intelligence. But several administrative pain points are already strong candidates for automation:
- claims review and exception routing
- prior authorization prep
- inventory and demand forecasting
- discrepancy detection in 340B-related workflows
- documentation support and reporting prep
The value of these tools is not novelty. It is speed, consistency, and lower administrative drag.
Infusion care will keep shifting toward more accessible delivery models
Across the programs we work with, infusion demand keeps growing and more of that care is moving into lower-cost, outpatient-friendly settings. For many providers, this creates both opportunity and pressure.
On one side:
- more patients need ongoing infused therapies
- local access remains uneven
- outpatient convenience is increasingly valuable
On the other:
- reimbursement can tighten
- staffing can be hard to scale
- operational complexity increases as volume rises
That tends to reward providers who treat infusion as an operational model, not just a service add-on.
What this means for FQHCs
For FQHCs, the convergence of 340B, TPA operations, and infusion growth creates a specific strategic question:
How do you preserve compliance and access while also building a financially sustainable care model?
In practice, the strongest answer usually includes:
- tighter pharmacy and claims visibility
- better use of analytics
- clearer site-of-care strategy
- stronger care continuity for infused therapies
- more deliberate use of 340B advantages
340B, TPA, and infusion services are three different operating areas, but they share a single requirement: better data visibility. Workflow maturity ends up mattering more than reactive problem-solving.
A practical readiness checklist
If you are preparing your organization, focus on the following:
- Audit the manual parts of your 340B process.
- Review whether your TPA model improves visibility or just moves work elsewhere.
- Identify infused therapies that may be better managed through a stronger site-of-care strategy.
- Tighten reporting and documentation before oversight pressure increases.
- Build a leadership view of pharmacy, reimbursement, and infusion economics together.
The organizations that come through strongest
They are not necessarily the biggest. They are the clearest.
They know:
- where their margin leaks out
- where compliance risk sits
- where patients encounter care friction
- where technology can remove repetitive administrative burden
That clarity is what turns policy uncertainty into a manageable operating problem.
This is best treated as a systems problem
The next wave of advantage will not come from chasing headlines. It will come from building better systems around the work you already do: cleaner 340B operations, smarter TPA infrastructure, and more efficient infusion delivery.
For healthcare leaders, that is the real opportunity.
Frequently Asked Questions
- What is the biggest 340B compliance risk for covered entities?
- The biggest risk is not one isolated rule change. It is operating a 340B program without strong documentation, clean data flow, and clear compliance ownership while oversight expectations continue to increase.
- How is 340B TPA strategy changing?
- TPA strategy is becoming more dependent on workflow automation, analytics, and real-time visibility. Providers increasingly need administrative partners and systems that reduce friction instead of simply taking tasks off their plate.
- Why does infusion strategy belong in an FQHC's operating plan?
- Because site-of-care decisions directly affect patient access, reimbursement, staffing pressure, and 340B economics. In our experience, outpatient infusion demand keeps growing, which makes those decisions harder to defer.
- What should FQHC leaders focus on first?
- Start with workflow maturity: documentation, reporting, claims visibility, and site-of-care economics. Those foundations make policy change easier to absorb.
Need help preparing for the next policy wave?
We help FQHCs and healthcare operators translate 340B, TPA, and infusion complexity into practical operating plans that are easier to manage and defend.
Request a strategy callWritten by
Remy Healthcare Team
340B & FQHC Specialists
The Remy team advises FQHCs and 340B covered entities on program management, infusion operations, and revenue optimization.
